Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Boston Scientific's operating assets for the quarter that ended in Mar. 2026 was MXN773,567 Mil. Boston Scientific's operating liabilities for the quarter that ended in Mar. 2026 was MXN130,160 Mil. Boston Scientific's Total Assets for the quarter that ended in Dec. 2025 was MXN786,363 Mil. Therefore, Boston Scientific's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.82.
Boston Scientific Scaled Net Operating Assets Related Terms
Boston Scientific Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Boston Scientific's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific Scaled Net Operating Assets Chart
MEX:BSX vs EW, GEHC, MDT: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Boston Scientific's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Boston Scientific's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.82 mean?
Boston Scientific (MEX:BSX) has a Scaled Net Operating Assets of 0.82 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Boston Scientific and its competitors.
Is Boston Scientific's Scaled Net Operating Assets too high?
Boston Scientific's current Scaled Net Operating Assets is 0.82. Overall, Boston Scientific has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Scaled Net Operating Assets compare to EW and GEHC?
Boston Scientific's Scaled Net Operating Assets of 0.82 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Boston Scientific and its competitors. Boston Scientific's current Scaled Net Operating Assets is 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (MEX:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,851.91, compared to a current price of MXN745.23 — trading 59.8% below its estimated fair value. The current Scaled Net Operating Assets is 0.82. Boston Scientific's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Boston Scientific (MEX:BSX), the current Scaled Net Operating Assets is 0.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (MEX:BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of MXN745.23 is trading 59.8% below its estimated GF Value™ of MXN1,851.91.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for MEX:BSX:
Scaled Net Operating Assets: 0.82
GF Value™: MXN1,851.91 vs. price of MXN745.23 (59.8% below fair value)
No single metric tells the full story. See the MEX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
85GF Score
Get the complete analysis for MEX:BSX
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BSX has been successfully added to your 
